How I treat multiple myeloma in younger patients

Alexander Keith Stewart, Paul G. Richardson, Jesus F. San-Miguel

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Therapeutic options for multiple myeloma (MM) patients have changed quickly in recent years and uncertainty has arisen about optimal approaches to therapy. A reasonable goal of MM treatment in younger "transplant eligible" patients is to initiate therapy with a target goal of durable complete remission, and the anticipated consequence of long-term disease control. To achieve this goal we recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortezomib, lenalidomide, thalidomide, cyclophosphamide, and corticosteriods) which when employed together elicit frequent, rapid, and deep responses.We recommend consolidation with high-dose melphalan and autologous stem cell transplantation in the majority of patients willing and able to undergo this procedure and subsequent maintenance therapy, especially in those failing to achieve a complete response or at high risk for early relapse based on prognostic, genetically defined risk factors. Defining genetic risk for early relapse is therefore an important aspect of early diagnostic testing and attention to minimizing expected toxicities once therapy begins is critical in ensuring the efficacy of modern combination therapy approaches. When access to newer drugs is restricted participation in clinical trials should be pursued.

Original languageEnglish (US)
Pages (from-to)5436-5443
Number of pages8
JournalBlood
Volume114
Issue number27
DOIs
StatePublished - Dec 24 2009

Fingerprint

Multiple Myeloma
Disease control
Transplants
Melphalan
Thalidomide
Chemotherapy
Stem cells
Consolidation
Cyclophosphamide
Toxicity
Therapeutics
Testing
Recurrence
Pharmaceutical Preparations
Stem Cell Transplantation
Combination Drug Therapy
Uncertainty
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

How I treat multiple myeloma in younger patients. / Stewart, Alexander Keith; Richardson, Paul G.; San-Miguel, Jesus F.

In: Blood, Vol. 114, No. 27, 24.12.2009, p. 5436-5443.

Research output: Contribution to journalArticle

Stewart, AK, Richardson, PG & San-Miguel, JF 2009, 'How I treat multiple myeloma in younger patients', Blood, vol. 114, no. 27, pp. 5436-5443. https://doi.org/10.1182/blood-2009-07-204651
Stewart, Alexander Keith ; Richardson, Paul G. ; San-Miguel, Jesus F. / How I treat multiple myeloma in younger patients. In: Blood. 2009 ; Vol. 114, No. 27. pp. 5436-5443.
@article{9962a63c1338428cb9122f81c7f4a49d,
title = "How I treat multiple myeloma in younger patients",
abstract = "Therapeutic options for multiple myeloma (MM) patients have changed quickly in recent years and uncertainty has arisen about optimal approaches to therapy. A reasonable goal of MM treatment in younger {"}transplant eligible{"} patients is to initiate therapy with a target goal of durable complete remission, and the anticipated consequence of long-term disease control. To achieve this goal we recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortezomib, lenalidomide, thalidomide, cyclophosphamide, and corticosteriods) which when employed together elicit frequent, rapid, and deep responses.We recommend consolidation with high-dose melphalan and autologous stem cell transplantation in the majority of patients willing and able to undergo this procedure and subsequent maintenance therapy, especially in those failing to achieve a complete response or at high risk for early relapse based on prognostic, genetically defined risk factors. Defining genetic risk for early relapse is therefore an important aspect of early diagnostic testing and attention to minimizing expected toxicities once therapy begins is critical in ensuring the efficacy of modern combination therapy approaches. When access to newer drugs is restricted participation in clinical trials should be pursued.",
author = "Stewart, {Alexander Keith} and Richardson, {Paul G.} and San-Miguel, {Jesus F.}",
year = "2009",
month = "12",
day = "24",
doi = "10.1182/blood-2009-07-204651",
language = "English (US)",
volume = "114",
pages = "5436--5443",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "27",

}

TY - JOUR

T1 - How I treat multiple myeloma in younger patients

AU - Stewart, Alexander Keith

AU - Richardson, Paul G.

AU - San-Miguel, Jesus F.

PY - 2009/12/24

Y1 - 2009/12/24

N2 - Therapeutic options for multiple myeloma (MM) patients have changed quickly in recent years and uncertainty has arisen about optimal approaches to therapy. A reasonable goal of MM treatment in younger "transplant eligible" patients is to initiate therapy with a target goal of durable complete remission, and the anticipated consequence of long-term disease control. To achieve this goal we recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortezomib, lenalidomide, thalidomide, cyclophosphamide, and corticosteriods) which when employed together elicit frequent, rapid, and deep responses.We recommend consolidation with high-dose melphalan and autologous stem cell transplantation in the majority of patients willing and able to undergo this procedure and subsequent maintenance therapy, especially in those failing to achieve a complete response or at high risk for early relapse based on prognostic, genetically defined risk factors. Defining genetic risk for early relapse is therefore an important aspect of early diagnostic testing and attention to minimizing expected toxicities once therapy begins is critical in ensuring the efficacy of modern combination therapy approaches. When access to newer drugs is restricted participation in clinical trials should be pursued.

AB - Therapeutic options for multiple myeloma (MM) patients have changed quickly in recent years and uncertainty has arisen about optimal approaches to therapy. A reasonable goal of MM treatment in younger "transplant eligible" patients is to initiate therapy with a target goal of durable complete remission, and the anticipated consequence of long-term disease control. To achieve this goal we recommend induction therapy with multi-agent combination chemotherapies (usually selected from bortezomib, lenalidomide, thalidomide, cyclophosphamide, and corticosteriods) which when employed together elicit frequent, rapid, and deep responses.We recommend consolidation with high-dose melphalan and autologous stem cell transplantation in the majority of patients willing and able to undergo this procedure and subsequent maintenance therapy, especially in those failing to achieve a complete response or at high risk for early relapse based on prognostic, genetically defined risk factors. Defining genetic risk for early relapse is therefore an important aspect of early diagnostic testing and attention to minimizing expected toxicities once therapy begins is critical in ensuring the efficacy of modern combination therapy approaches. When access to newer drugs is restricted participation in clinical trials should be pursued.

UR - http://www.scopus.com/inward/record.url?scp=76249096571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249096571&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-204651

DO - 10.1182/blood-2009-07-204651

M3 - Article

C2 - 19861683

AN - SCOPUS:76249096571

VL - 114

SP - 5436

EP - 5443

JO - Blood

JF - Blood

SN - 0006-4971

IS - 27

ER -